scholarly journals 2016 ISCB Overton Prize awarded to Debora Marks

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1575
Author(s):  
Christiana N. Fogg ◽  
Diane E. Kovats

The International Society for Computational Biology (ISCB) recognizes the achievements of an early- to mid-career scientist with the Overton Prize each year. The Overton Prize was established to honor the untimely loss of Dr. G. Christian Overton, a respected computational biologist and founding ISCB Board member. Winners of the Overton Prize are independent investigators in the early to middle phases of their careers who are selected because of their significant contributions to computational biology through research, teaching, and service. 2016 will mark the fifteenth bestowment of the ISCB Overton Prize.  ISCB is pleased to confer this award the to Debora Marks, Assistant Professor of Systems Biology and director of the Raymond and Beverly Sackler Laboratory for Computational Biology at Harvard Medical School.

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 999
Author(s):  
Christiana N. Fogg ◽  
Diane E. Kovats ◽  
Bonnie Berger

The International Society for Computational Biology (ISCB) each year recognizes the achievements of an early to mid-career scientist with the Overton Prize. This prize honors the untimely death of Dr. G. Christian Overton, an admired computational biologist and founding ISCB Board member. Winners of the Overton Prize are independent investigators who are in the early to middle phases of their careers and are selected because of their significant contributions to computational biology through research, teaching, and service. ISCB is pleased to recognize Dr. Christoph Bock, Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, Austria, as the 2017 winner of the Overton Prize. Bock will be presenting a keynote presentation at the 2017 International Conference on Intelligent Systems for Molecular Biology/European Conference on Computational Biology (ISMB/ECCB) in Prague, Czech Republic being held during July 21-25, 2017.


2019 ◽  
Vol 216 (5) ◽  
pp. 1005-1009 ◽  
Author(s):  
Miguel Jimenez ◽  
Robert Langer ◽  
Giovanni Traverso

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.


Sign in / Sign up

Export Citation Format

Share Document